Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 15

1.

The prostaglandin E(2) system: a toolbox for skeletal repair?

Gelse K, Beyer C.

Arthritis Rheum. 2011 Apr;63(4):871-3. doi: 10.1002/art.30153. No abstract available.

2.

High-affinity inhibitors of human NAD-dependent 15-hydroxyprostaglandin dehydrogenase: mechanisms of inhibition and structure-activity relationships.

Niesen FH, Schultz L, Jadhav A, Bhatia C, Guo K, Maloney DJ, Pilka ES, Wang M, Oppermann U, Heightman TD, Simeonov A.

PLoS One. 2010 Nov 2;5(11):e13719. doi: 10.1371/journal.pone.0013719.

3.

Synthesis and SAR of thiazolidinedione derivatives as 15-PGDH inhibitors.

Wu Y, Tai HH, Cho H.

Bioorg Med Chem. 2010 Feb 15;18(4):1428-33. doi: 10.1016/j.bmc.2010.01.016. Epub 2010 Jan 11.

PMID:
20122835
4.

Involvement of PGE2 and PGDH but not COX-2 in thrombin-induced cortical neuron apoptosis.

Thirumangalakudi L, Rao HV, Grammas P.

Neurosci Lett. 2009 Mar 13;452(2):172-5. doi: 10.1016/j.neulet.2009.01.045. Epub 2009 Jan 21.

5.

Thematic Review Series: Proteomics. An integrated omics analysis of eicosanoid biology.

Buczynski MW, Dumlao DS, Dennis EA.

J Lipid Res. 2009 Jun;50(6):1015-38. doi: 10.1194/jlr.R900004-JLR200. Epub 2009 Feb 24. Review. Erratum in: J Lipid Res. 2009 Jul;50(7):1505.

6.

Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries.

Inglese J, Auld DS, Jadhav A, Johnson RL, Simeonov A, Yasgar A, Zheng W, Austin CP.

Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11473-8. Epub 2006 Jul 24.

7.

Adamantyl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1.

Olson S, Aster SD, Brown K, Carbin L, Graham DW, Hermanowski-Vosatka A, LeGrand CB, Mundt SS, Robbins MA, Schaeffer JM, Slossberg LH, Szymonifka MJ, Thieringer R, Wright SD, Balkovec JM.

Bioorg Med Chem Lett. 2005 Oct 1;15(19):4359-62.

PMID:
16039856
8.

15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers.

Yan M, Rerko RM, Platzer P, Dawson D, Willis J, Tong M, Lawrence E, Lutterbaugh J, Lu S, Willson JK, Luo G, Hensold J, Tai HH, Wilson K, Markowitz SD.

Proc Natl Acad Sci U S A. 2004 Dec 14;101(50):17468-73. Epub 2004 Dec 1.

9.

Copper-diamine-catalyzed N-arylation of pyrroles, pyrazoles, indazoles, imidazoles, and triazoles.

Antilla JC, Baskin JM, Barder TE, Buchwald SL.

J Org Chem. 2004 Aug 20;69(17):5578-87. Erratum in: J Org Chem. 2004 Sep 17;69(19):6514.

PMID:
15307726
10.

COX-2 and beyond: Approaches to prostaglandin inhibition in human disease.

FitzGerald GA.

Nat Rev Drug Discov. 2003 Nov;2(11):879-90. Review. No abstract available.

PMID:
14668809
11.
12.

Prostaglandin catabolizing enzymes.

Tai HH, Ensor CM, Tong M, Zhou H, Yan F.

Prostaglandins Other Lipid Mediat. 2002 Aug;68-69:483-93. Review.

PMID:
12432938
13.

Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells.

Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN.

Cancer Res. 1998 Jan 15;58(2):362-6.

15.

PGE2: a mediator of corneal endothelial wound repair in vitro.

Joyce NC, Meklir B.

Am J Physiol. 1994 Jan;266(1 Pt 1):C269-75.

PMID:
8304421

Supplemental Content

Support Center